ISRCTN68093791已完成1 期
A phase I dose-escalating and safety study of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophago-gastric adenocarcinoma
niversity of Oxford (UK)0 个研究点目标入组 24 人开始时间: 2012年4月27日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
2020 Results article in https://www.ncbi.nlm.nih.gov/pubmed/31765988 results (added 26/11/2019)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age = 18 years
- •2. WHO performance status 01
- •3. Adequate respiratory and cardiac function
- •4. Able to give informed consent and be capable of cooperating with protocol
- •5. Haematological and biochemical indices within the ranges shown below:
- •5.1. Haemoglobin (Hb) =10g/dl
- •5.2. Neutrophils = 1500/µl
- •5.3. Platelet count = 100.000/µl
- •5.4. AST or ALT = 3 ULN, alkaline phosphatase = 2x ULN
- •5.5. Serum Bilirubin = 1.5 ULN
- •5.6. Creatinine Clearance = 50ml/min
- •6. Able to swallow oral medication
- •7. Women of child bearing potential must use an acceptable method of contraception during the study, and have a negative pregnancy test
- •8. Male patients must use a barrier method of contraception - male condom (female condom or diaphragm are not acceptable) during the study.
- •9. For the dose escalation phase patients with locally advanced or metastatic oesophageal or gastro-oesophageal junction adenocarcinoma (including Siewert type I and II). In the dose expansion phase
- •10. Histologically confirmed carcinoma of the oesophagus and gastrooesophageal junction [GOJ]
- •11. Siewert Type I and II Operable disease: any combination T13 / N01 [BUT EXCLUDES T1N0]
- •12. T4 involvement of mediastinal pleura and diaphragmatic crus where the MDT consider this resectable.
- •13. Deemed suitable for neoadjuvant chemotherapy by regional upper gastrointestinal Multi-Disciplinary Team;
- •14. Target Gender: Male & Female
- •15. Lower Age Limit 18 years
排除标准
- •1. Previous chemotherapy for oesophagogastric adenocarcinoma
- •2. Siewert Type III GOJ tumours and gastric cancer
- •3. Squamous cell pathology
- •4. Uncontrolled angina, myocardial infarction within 6 months, heart failure or impaired LV function on echocardiogram/MUGA, uncontrolled arrhythmias.
- •5. History of interstitial lung disease
- •6. Known peripheral neuropathy >Grade 1
- •7. Other experimental treatment = 4 weeks prior to this study (including chemotherapy and immunotherapy)
- •8. Known or expected dihydropyridime dehydrogenase deficiency
- •9. Resting ECG with QTc >480msec at 2 or more time points within a 24h period
- •10. Requirement for medication known to inhibit or induce CYP3A4 or 2D6, or medication known to prolong QT interval
- •11. History of other malignancy less than 5 years before the diagnosis of oesophageal cancer, EXCLUDING the following: Non-melanoma skin cancer, in situ carcinoma of the cervix treated surgically with curative intent, other malignant tumours that have been treated curatively and patient is deemed disease-free
- •12. Active infections (including chronic hepatitis type B or C and HIV infection if status known), severe immunologic defect, compromised bone marrow function
- •13. Prior diagnosis of dry eye syndrome or eyelid/eyelash abnormalities. History of eye injury, corneal surgery, orbital irradiation, collagen vascular, chronic inflammatory or denegerative disease with eye involvement, clinically significant ocular surface disease 14. Known hypersensitivity to any component of chemotherapy
- •15. Pregnancy, inadequate or unreliable contraceptive measures during participation in the trial; breast feeding.
- •16. Other psychological, social or medical condition, physical examination finding or a laboratory abnormality that the Investigator considers would make the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of trial results.
研究者
相似试验
已完成
1 期
A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.Advanced Solid TumoursNCT02579226AstraZeneca72
已完成
1 期
Open Label, Dose Escalation Phase I Study of AZD2281Advanced Solid MalignanciesNCT00572364AstraZeneca18
终止
1 期
A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.Solid TumourAdvanced Solid MalignanciesChild-Pugh A to B7 Advanced Hepatocellular CarcinomaEGFR and/or ROS Mutant NSCLCLung Metastasis CarcinomaGastric CancerNCT01219543AstraZeneca47
终止
1 期
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid TumoursSolid MalignanciesNCT01112397AstraZeneca72
已完成
1 期
Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy SubjectsAlzheimer's DiseaseNCT00687141AstraZeneca112